Clinicians evaluating potential tirzepatide and sermorelin combination therapy must conduct comprehensive assessment addressing multiple clinical domains before initiating treatment
People dealing with both conditions where the obesity is likely contributing to mental health symptoms (through inflammation, metabolic effects, weight stigma) and the mental health symptoms are contributing to obesity (through effects on eating, activity, sleep, stress hormones)
There is a transition period that researchers sometimes call metabolic adaptation, and during this phase, energy levels can drop noticeably
Other side effects include dizziness, mild tachycardia, infections, headaches, and indigestion
This is an educational research reference about FOXO4-DRI, not medical advice or a treatment plan